94 related articles for article (PubMed ID: 10851509)
21. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas.
Raspadori D; Lauria F; Ventura MA; Tazzari PL; Ferrini S; Miggiano MC; Rondelli D; Tura S
Ann Hematol; 1995 Oct; 71(4):175-9. PubMed ID: 7578523
[TBL] [Abstract][Full Text] [Related]
22. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
[TBL] [Abstract][Full Text] [Related]
23. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
[TBL] [Abstract][Full Text] [Related]
25. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
26. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.
Valteau-Couanet D; Rubie H; Meresse V; Farace F; Brandely M; Hartmann O
Bone Marrow Transplant; 1995 Oct; 16(4):515-20. PubMed ID: 8528166
[TBL] [Abstract][Full Text] [Related]
27. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation.
Favrot MC; Michon J; Floret D; Cochat C; Negrier S; Mathiot C; Coze C; Zucker JM; Franks CR; Bouffet E
Pediatr Hematol Oncol; 1990; 7(3):275-84. PubMed ID: 2206868
[TBL] [Abstract][Full Text] [Related]
29. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma.
Gottlieb DJ; Prentice HG; Mehta AB; Galazka AR; Heslop HE; Hoffbrand AV; Brenner MK
Br J Haematol; 1990 Aug; 75(4):499-505. PubMed ID: 2119792
[TBL] [Abstract][Full Text] [Related]
30. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
[TBL] [Abstract][Full Text] [Related]
31. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
33. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.
Castriconi R; Dondero A; Cilli M; Ognio E; Pezzolo A; De Giovanni B; Gambini C; Pistoia V; Moretta L; Moretta A; Corrias MV
Cancer Immunol Immunother; 2007 Nov; 56(11):1733-42. PubMed ID: 17426969
[TBL] [Abstract][Full Text] [Related]
34. Natural killer (NK) and T cell-associated surface marker expression following allogeneic and autologous bone marrow transplantation (BMT).
Nagler A; Rabinowitz R; Rosengolts-Rat J; Condiotti R; Schlesinger M
J Hematother Stem Cell Res; 2000 Feb; 9(1):63-75. PubMed ID: 10738973
[TBL] [Abstract][Full Text] [Related]
35. [LAK cells and immunotherapy of cancer].
Khayat D; Weil M; Soubrane C; Jacquillat C
Bull Cancer; 1988; 75(1):3-7. PubMed ID: 3258774
[TBL] [Abstract][Full Text] [Related]
36. NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Kanold J; Paillard C; Tchirkov A; Lang P; Kelly A; Halle P; Isfan F; Merlin E; Marabelle A; Rochette E; Deméocq F
Pediatr Blood Cancer; 2012 Oct; 59(4):739-42. PubMed ID: 22180305
[TBL] [Abstract][Full Text] [Related]
37. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
[TBL] [Abstract][Full Text] [Related]
38. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy with IL2 by constant infusion and weekly doxorubicin.
Paciucci PA; Bekesi JG; Ryder JS; Odchimar R; Chahinian PA; Holland JF
Am J Clin Oncol; 1991 Aug; 14(4):341-8. PubMed ID: 1830717
[TBL] [Abstract][Full Text] [Related]
40. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA
Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
